The Market Doesn't Like What It Sees From Telix Pharmaceuticals Limited's (ASX:TLX) Revenues Yet As Shares Tumble 26%
Dec 31
Have your own idea? Try our Stock Screener
Australian (ASX) Biotech Industry Analysis
UpdatedJan 11, 2026
DataAggregated Company Financials
Companies33
- 7D1.5%
- 3M-15.5%
- 1Y-37.1%
- YTD1.5%
In the last week, the Biotech industry is up 1.5%, with CSL up 1.4%. However, the industry is down 37% over the past year. As for the next few years, earnings are expected to grow by 14% per annum.
Industry Valuation and Performance
Has the Australian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 11 Jan 2026 | AU$96.8b | AU$24.6b | AU$4.0b | 18.7x | 24.1x | 3.9x |
| Tue, 09 Dec 2025 | AU$102.5b | AU$24.8b | AU$4.1b | 19.8x | 25.3x | 4.1x |
| Thu, 06 Nov 2025 | AU$97.8b | AU$25.4b | AU$4.2b | 18.4x | 23.5x | 3.9x |
| Sat, 04 Oct 2025 | AU$113.7b | AU$24.9b | AU$4.1b | 22.1x | 27.9x | 4.6x |
| Mon, 01 Sep 2025 | AU$114.3b | AU$25.1b | AU$4.1b | 22.5x | 27.7x | 4.6x |
| Wed, 30 Jul 2025 | AU$145.5b | AU$24.4b | AU$3.9b | 48.5x | 37.7x | 6x |
| Fri, 27 Jun 2025 | AU$129.9b | AU$24.3b | AU$3.8b | 20.4x | 33.8x | 5.3x |
| Sun, 25 May 2025 | AU$133.4b | AU$24.5b | AU$3.9b | 21x | 34.5x | 5.4x |
| Tue, 22 Apr 2025 | AU$129.6b | AU$24.8b | AU$3.9b | 20.5x | 33.1x | 5.2x |
| Thu, 20 Mar 2025 | AU$136.1b | AU$25.1b | AU$4.0b | 21.7x | 34.3x | 5.4x |
| Sat, 15 Feb 2025 | AU$140.8b | AU$24.9b | AU$3.8b | 22.8x | 37.2x | 5.6x |
| Mon, 13 Jan 2025 | AU$153.0b | AU$25.0b | AU$3.7b | 24.1x | 40.8x | 6.1x |
| Wed, 11 Dec 2024 | AU$150.3b | AU$24.0b | AU$3.6b | 25.5x | 41.9x | 6.3x |
| Fri, 08 Nov 2024 | AU$150.0b | AU$23.1b | AU$3.4b | 26.9x | 43.9x | 6.5x |
| Sun, 06 Oct 2024 | AU$152.1b | AU$22.7b | AU$3.3b | 27.9x | 45.4x | 6.7x |
| Tue, 03 Sep 2024 | AU$159.1b | AU$22.8b | AU$3.4b | 30x | 47.4x | 7x |
| Thu, 01 Aug 2024 | AU$160.8b | AU$22.7b | AU$3.3b | 32.1x | 48.2x | 7.1x |
| Sat, 29 Jun 2024 | AU$153.7b | AU$22.1b | AU$3.2b | 32x | 47.3x | 6.9x |
| Mon, 27 May 2024 | AU$145.8b | AU$22.2b | AU$3.2b | 31.1x | 45x | 6.6x |
| Wed, 24 Apr 2024 | AU$144.0b | AU$22.8b | AU$3.3b | 30x | 43.1x | 6.3x |
| Fri, 22 Mar 2024 | AU$141.7b | AU$22.3b | AU$3.3b | 29.6x | 43.5x | 6.4x |
| Sun, 18 Feb 2024 | AU$144.5b | AU$22.3b | AU$3.3b | 31x | 44x | 6.5x |
| Tue, 16 Jan 2024 | AU$147.1b | AU$20.6b | AU$2.7b | 34.3x | 54x | 7.1x |
| Thu, 14 Dec 2023 | AU$138.5b | AU$20.9b | AU$2.8b | 32.9x | 49.8x | 6.6x |
| Sat, 11 Nov 2023 | AU$128.5b | AU$21.6b | AU$2.9b | 30.2x | 44.5x | 6x |
| Mon, 09 Oct 2023 | AU$128.1b | AU$21.5b | AU$2.8b | 29.7x | 45.4x | 6x |
| Wed, 06 Sep 2023 | AU$138.4b | AU$21.6b | AU$2.8b | 33.3x | 48.9x | 6.4x |
| Fri, 04 Aug 2023 | AU$137.7b | AU$18.4b | AU$2.4b | 36.2x | 57.6x | 7.5x |
| Sun, 02 Jul 2023 | AU$142.7b | AU$18.1b | AU$2.3b | 37.8x | 61.2x | 7.9x |
| Tue, 30 May 2023 | AU$157.4b | AU$18.4b | AU$2.4b | 40.4x | 66x | 8.6x |
| Thu, 27 Apr 2023 | AU$156.3b | AU$18.2b | AU$2.3b | 41.8x | 66.6x | 8.6x |
| Sat, 25 Mar 2023 | AU$146.9b | AU$18.1b | AU$2.3b | 39.3x | 62.7x | 8.1x |
| Mon, 20 Feb 2023 | AU$151.9b | AU$17.3b | AU$2.3b | 51.3x | 66.5x | 8.8x |
| Wed, 18 Jan 2023 | AU$148.4b | AU$15.5b | AU$2.5b | 52.2x | 60.5x | 9.6x |
Price to Earnings Ratio
60.5x
Current Industry PE
- Investors are pessimistic on the Australian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 24.1x which is lower than its 3-year average PE of 44.9x.
- The 3-year average PS ratio of 6.4x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have grown 18% per year over the last three years.
- Revenues for these companies have grown 17% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Australian Healthcare industry?
| AU Market | 0.16% | |
| Healthcare | -0.13% | |
| Biotech | 1.52% | |
| Biotech | 1.52% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| CSL CSL | AU$174.29 | 1.4% +AU$1.1b | -38.9% | PE18.7x | |
| MSB Mesoblast | AU$3.07 | 10.8% +AU$384.9m | 9.3% | PS153.2x | |
| PYC PYC Therapeutics | AU$1.68 | 1.5% +AU$14.6m | 31.3% | PS41.7x | |
| ARX Aroa Biosurgery | AU$0.77 | 4.8% +AU$12.1m | -1.9% | PS3.4x | |
| NXN Nexsen | AU$0.20 | 30.0% +AU$9.0m | n/a | PS41.9x |
